» Articles » PMID: 34066560

Probiotics, Photobiomodulation, and Disease Management: Controversies and Challenges

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Jun 2
PMID 34066560
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

In recent decades, researchers around the world have been studying intensively how micro-organisms that are present inside living organisms could affect the main processes of life, namely health and pathological conditions of mind or body. They discovered a relationship between the whole microbial colonization and the initiation and development of different medical disorders. Besides already known probiotics, novel products such as postbiotics and paraprobiotics have been developed in recent years to create new non-viable micro-organisms or bacterial-free extracts, which can provide benefits to the host with additional bioactivity to probiotics, but without the risk of side effects. The best alternatives in the use of probiotics and postbiotics to maintain the health of the intestinal microbiota and to prevent the attachment of pathogens to children and adults are highlighted and discussed as controversies and challenges. Updated knowledge of the molecular and cellular mechanisms involved in the balance between microbiota and immune system for the introspection on the gut-lung-brain axis could reveal the latest benefits and perspectives of applied photobiomics for health. Multiple interconditioning between photobiomodulation (PBM), probiotics, and the human microbiota, their effects on the human body, and their implications for the management of viral infectious diseases is essential. Coupled complex PBM and probiotic interventions can control the microbiome, improve the activity of the immune system, and save the lives of people with immune imbalances. There is an urgent need to seek and develop innovative treatments to successfully interact with the microbiota and the human immune system in the coronavirus crisis. In the near future, photobiomics and metabolomics should be applied innovatively in the SARS-CoV-2 crisis (to study and design new therapies for COVID-19 immediately), to discover how bacteria can help us through adequate energy biostimulation to combat this pandemic, so that we can find the key to the hidden code of communication between RNA viruses, bacteria, and our body.

Citing Articles

Microbiome structure in healthy and pregnant women and importance of vaginal dysbiosis in spontaneous abortion.

Eslami M, Naderian R, Ahmadpour A, Shushtari A, Maleki S, Mohammadian P Front Cell Infect Microbiol. 2025; 14:1401610.

PMID: 40046910 PMC: 11881085. DOI: 10.3389/fcimb.2024.1401610.


Utilization of Probiotic-Derived Extracellular Vesicles as Postbiotics and Their Role in Mental Health Therapeutics.

Baek J, Lee S, Lee J, Park J, Choi E, Kang S Food Sci Anim Resour. 2024; 44(6):1252-1265.

PMID: 39554832 PMC: 11564138. DOI: 10.5851/kosfa.2024.e92.


Microbiota and glioma: a new perspective from association to clinical translation.

Wang W, Ou Z, Huang X, Wang J, Li Q, Wen M Gut Microbes. 2024; 16(1):2394166.

PMID: 39185670 PMC: 11352717. DOI: 10.1080/19490976.2024.2394166.


Defined Pig Microbiota Mixture as Promising Strategy against Salmonellosis in Gnotobiotic Piglets.

Modrackova N, Horvathova K, Mekadim C, Splichal I, Splichalova A, Amin A Animals (Basel). 2024; 14(12).

PMID: 38929398 PMC: 11200913. DOI: 10.3390/ani14121779.


What can we learn from treatments of oral lichen planus?.

Wu T, Bai Y, Jing Y, Chen F Front Cell Infect Microbiol. 2024; 14:1279220.

PMID: 38426013 PMC: 10902003. DOI: 10.3389/fcimb.2024.1279220.


References
1.
Lievin-Le Moal V, Servin A . Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents. Clin Microbiol Rev. 2014; 27(2):167-99. PMC: 3993101. DOI: 10.1128/CMR.00080-13. View

2.
Unger S, Stintzi A, Shah P, Mack D, OConnor D . Gut microbiota of the very-low-birth-weight infant. Pediatr Res. 2014; 77(1-2):205-13. PMC: 7094749. DOI: 10.1038/pr.2014.162. View

3.
Vuotto C, Longo F, Donelli G . Probiotics to counteract biofilm-associated infections: promising and conflicting data. Int J Oral Sci. 2014; 6(4):189-94. PMC: 5153589. DOI: 10.1038/ijos.2014.52. View

4.
. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018; 18(11):1211-1228. PMC: 6202444. DOI: 10.1016/S1473-3099(18)30362-1. View

5.
Landaburu M, Lopez Daneri G, Relloso S, Zarlenga L, Vinante M, Teresa Mujica M . Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient. Rev Argent Microbiol. 2019; 52(1):27-30. DOI: 10.1016/j.ram.2019.04.002. View